NIH RFA · NINDS · R61, R33
RFA-NS-25-023: HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This funding opportunity is part of a suite of NOFOs within the NIH HEAL Initiative to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal is to encourage initial translational efforts that will support a drug discovery program and advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program. The scope will therefore be focused on development of assays to support a distinct testing funnel, screening efforts to identify hits, and initial characterization of hits and potential therapeutic agents (including small molecules, biologics, and natural products).
- NOFO number
- RFA-NS-25-023
- Type
- RFA
- Activity code
- R61R33
- Primary institute
- NINDS · National Institute of Neurological Disorders and Stroke
- Clinical trials
- Not Allowed
- Posted
- Sep 18, 2024
- Opens
- Dec 28, 2024
- Expires
- Jan 16, 2027
RFA-NS-25-023 due dates
1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| January 28, 2025 | January 28, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| May 16, 2025 | May 16, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| September 17, 2025 | September 17, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| January 16, 2026 | January 16, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| May 15, 2026 | May 15, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| September 17, 2026 | September 17, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| January 15, 2027 | January 15, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
Projects funded under RFA-NS-25-023
NIH RePORTER lists 6 projects funded under RFA-NS-25-023 in FY2022–FY2026, with $5.2M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
6
Distinct projects, FY2022–FY2026
New awards
6
Type 1 (new project) award records
NIH funding
$5.2M
Award dollars under RFA-NS-25-023, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 6 | 6 | $5.2M |
Institutions with the most funding
- University of Massachusetts Lowell$1.3M · 1 project
- Massachusetts General Hospital$1.1M · 1 project
- Washington University$816K · 1 project
- Rutgers Biomedical and Health Sciences$787K · 1 project
- Weill Medical Coll of Cornell Univ$635K · 1 project
- University of Miami School of Medicine$594K · 1 project
Funding institutes
- NINDS$5.2M · 6
Activity codes funded
- R616 records
Most recent new awards
- Generation of a CCL2-CGRP bispecific neutralizing antibody to treat chronic post-traumatic headache (opens NIH RePORTER)
Washington University · 1R61NS146000-01A1 · NINDS · Notice Sep 17, 2026
$816KR61
- Development and validation of human NIS-lncRNA ASO as a novel potential drug to neuropathic pain treatment (opens NIH RePORTER)
Rutgers Biomedical and Health Sciences · 1R61NS145978-01 · NINDS · Notice Sep 3, 2026
$787KR61
- Human(h) HCN1-Selective Nanobodies for use in the Development of Novel, Non-Opioid Antihyperalgesics for the Treatment of Neuropathic Pain (opens NIH RePORTER)
Weill Medical Coll of Cornell Univ · 1R61NS147892-01 · NINDS · Notice Aug 28, 2026
$635KR61
- Developing non-viral gene therapy for acute pain treatment (opens NIH RePORTER)
Massachusetts General Hospital · 1R61NS149953-01 · NINDS · Notice Aug 19, 2026
$1.1MR61
- High Throughput Screening for Neuropeptide S Receptor Positive Allosteric Modulators (opens NIH RePORTER)
University of Miami School of Medicine · 1R61NS143600-01A1 · NINDS · Notice Aug 14, 2026
$594KR61
- Non-Addictive Analgesic Discovery from Marine Microbial Natural Products (opens NIH RePORTER)
University of Massachusetts Lowell · 1R61NS145983-01 · NINDS · Notice Jun 1, 2026
$1.3MR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
10 NIH institutes and offices take applications under RFA-NS-25-023. Contact the program officer at the institute that fits your research before applying.
- NINDS · National Institute of Neurological Disorders and Stroke
- NEI · National Eye Institute
- NIA · National Institute on Aging
- NIAAA · National Institute on Alcohol Abuse and Alcoholism
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NIDCR · National Institute of Dental and Craniofacial Research
- NIDDK · National Institute of Diabetes and Digestive and Kidney Diseases
- NCCIH · National Center for Complementary and Integrative Health
- NCI · National Cancer Institute
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022
Implementation Details for the NIH Data Management and Sharing Policy.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to direct costs of 350,000 per year and need to reflect the actual needs of the proposed project.
- Project period
- The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed three years, with no more than two years for the R61 phase and no more than two years for the R33 phase. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The NIH HEAL Helping to End Addiction Long-term) Initiative intends to commit an estimated total of 2,500,000 to fund 4-5 awards in FY 2025. Awards pursuant to this funding opportunity are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-NS-25-012.
Other open NOFOs for R61, R33
- PAR-25-225Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)NINDS · next due Oct 20, 2026
- PAR-25-024Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)NINDS · next due Oct 20, 2026
- PAR-25-059Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)NINDS · next due Oct 20, 2026
- PAR-25-060Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)NINDS · next due Oct 20, 2026
- PAR-25-053Translational Neural Devices (R61/R33 - Clinical Trial Optional)NINDS · next due Jan 28, 2027
- PAR-27-045HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)NCCIH · next due Oct 30, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.